Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.

We apologize to the many laboratories whose contribution to this field could not be discussed or cited. Due to space limitations, many primary references were omitted. Support from the National Institutes of Health (R01 CA89578, R01 CA82578) and the Botwinick-Wolfensohn Foundation (in memory of Mr. and Mrs. Benjamin Botwinick) is gratefully acknowledged.

[1]  M. Toi,et al.  Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  E. Dejana,et al.  Inhibitors of Cyclo-Oxygenase , 1983 .

[3]  A. Barkun,et al.  The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. , 2003, Gastroenterology.

[4]  S. Narumiya,et al.  Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.

[5]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[6]  D. A. Dixon,et al.  Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. , 2001, The Journal of clinical investigation.

[7]  F. Marks,et al.  Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Narumiya,et al.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice , 2001, Nature Medicine.

[9]  J. Morrow,et al.  Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. , 1999, Cancer research.

[10]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[11]  J. Regan,et al.  Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 * , 2002, The Journal of Biological Chemistry.

[12]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[13]  C. Harris,et al.  Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. , 2003, Cancer research.

[14]  Andrew J. Dannenberg,et al.  Regulation of Cyclooxgenase-2 mRNA Stability by Taxanes , 2003, Journal of Biological Chemistry.

[15]  B. Evers,et al.  Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. , 2003, Cancer research.

[16]  L. Norton,et al.  Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.

[17]  R. DuBois,et al.  Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor* , 2003, Journal of Biological Chemistry.

[18]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[19]  G. Gasparini,et al.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? , 2003, The Lancet. Oncology.

[20]  P. Anderson,et al.  TIA‐1 is a translational silencer that selectively regulates the expression of TNF‐α , 2000 .

[21]  F. Ranelletti,et al.  Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Yukihiko Sugimoto,et al.  Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003, The Journal of experimental medicine.

[23]  D. Yankelevitz,et al.  Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[25]  H. Choy,et al.  Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? , 2003, Journal of the National Cancer Institute.

[26]  T. Hla,et al.  The RNA-binding Protein HuR Regulates the Expression of Cyclooxygenase-2* , 2003, Journal of Biological Chemistry.

[27]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[28]  A. Tarnawski,et al.  Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.

[29]  M. Huang,et al.  Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  O. Boutaud,et al.  Tristetraprolin Binds to the 3′-Untranslated Region of Cyclooxygenase-2 mRNA , 2003, The Journal of Biological Chemistry.

[31]  R. Langenbach,et al.  Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. , 2000, Cancer research.

[32]  J. Morrow,et al.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. , 2003, The Journal of clinical investigation.

[33]  P. Anderson,et al.  Regulation of Cyclooxygenase-2 Expression by the Translational Silencer TIA-1 , 2003, The Journal of experimental medicine.

[34]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[35]  N. Altorki,et al.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.

[36]  D. Goldenberg,et al.  Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. , 2002, Cancer research.

[37]  K. Subbaramaiah,et al.  Cyclooxygenase 2: a molecular target for cancer prevention and treatment. , 2003, Trends in pharmacological sciences.

[38]  S. Dey,et al.  Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.

[39]  T. Iwama,et al.  A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.